A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial

Plain-language guide to PMID 28854728 (2017): double-blind randomized controlled trial study of Kisspeptin-10 and Kisspeptin-54 in 62 women.

Key Facts

PMID: 28854728
Journal: Human reproduction (Oxford, England)
Year: 2017
Study type: Randomized Controlled Trial
Authors: Abbara A et al. (18 authors)
DOI: 10.1093/humrep/dex253
Registered trial: NCT01667406

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Kisspeptin-10 and Kisspeptin-54, published as a randomized controlled trial.

Kisspeptin acts at the hypothalamus to stimulate the release of an endogenous pool of GnRH from the hypothalamus.

Further studies are warranted to directly compare kisspeptin-54 to more established triggers of oocyte maturation.

Who Took Part

According to the abstract, 62 women were involved.

The age groups tagged for this paper are teenagers and adults, women only.

Phase-2 randomized placebo-controlled trial of 62 women at high risk of OHSS recruited between August 2015 and May 2016.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The women were allocated by chance, so the Kisspeptin-10 group and the comparison group should start out alike.

As a double-blind Kisspeptin-10 study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Kisspeptin-10 could be set against what happens without it.

Setting: Single centre study carried out at Hammersmith Hospital IVF unit, London, UK.

Secondary outcomes: Reproductive hormone levels, implantation rate and OHSS occurrence.

What Was Measured

PubMed files the paper under topics including Fertilization in Vitro, Kisspeptins, Oocyte Retrieval, Ovarian Hyperstimulation Syndrome, Ovulation Induction and Pregnancy Rate.

The authors tagged it with the keywords ICSI outcome, IVF, OHSS, oocyte maturation and trigger injection.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Kisspeptin-10 and Kisspeptin-54 in 62 women.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (Human reproduction (Oxford, England)), a journal based in England.

More context: the Kisspeptin-10 compound page and the Kisspeptin-54 compound page.

Our Notes on the Compounds

Kisspeptin-10: A hypothalamic signaling peptide that triggers GnRH, and through it LH and FSH.

Kisspeptin-54: The full-length 54-amino-acid kisspeptin, studied in people to trigger egg maturation in IVF; Kisspeptin-10 has its own page.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.